Open AccessCirculating cyclic adenosine monophosphate concentrations in milrinone treated paediatric patients after congenital heart surgery
Author(s) -
Katja M. Gist,
Armin Korst,
Stephanie J. Nakano,
Brian L. Stauffer,
Anis Karimpour-Fard,
Wenru Zhou,
Kristen Campbell,
Michael F. Wempe,
Carmen C. Sucharov,
Shelley D. Miyamoto
Publication year - 2021
Publication title -
cardiology in the young
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.386
H-Index - 54
eISSN - 1467-1107
pISSN - 1047-9511
DOI - 10.1017/s1047951121000251
Subject(s) - milrinone , medicine , adenosine , cardiology , heart disease , cyclic adenosine monophosphate , cardiac surgery , phosphodiesterase inhibitor , prospective cohort study , phosphodiesterase , endocrinology , anesthesia , inotrope , enzyme , biochemistry , receptor , chemistry
Milrinone is a phosphodiesterase type 3 inhibitor that results in a positive inotropic effect in the heart through an increase in cyclic adenosine monophosphate. The purpose of this study was to evaluate circulating cyclic adenosine monophosphate and milrinone concentrations in milrinone treated paediatric patients undergoing congenital heart surgery.